Financial Performance - The company reported a significant increase in revenue for the first half of 2024, achieving a total of 500 million RMB, representing a 25% growth compared to the same period last year[1]. - The company achieved operating revenue of CNY 402,286,721.86 in the first half of 2024, an increase of 27.85% compared to CNY 314,666,473.81 in the same period last year[16]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2024, representing a 20% year-over-year growth[102]. - The company reported a significant increase in revenue for the first half of 2024, with a year-over-year growth of 25%[106]. - The company reported a net profit margin of 15%, which is an improvement from 12% in the previous year[102]. - The company reported a net loss attributable to shareholders was CNY -236,845,848.07, a reduction in loss of CNY 16,775,025.19 compared to the previous year[18]. - The company reported a net loss for the first half of 2024 was RMB 2,469,094,798.57, compared to a net loss of RMB 2,232,408,924.58 in the same period of 2023, indicating an increase in losses of 10.6%[157]. User Growth and Market Expansion - User data indicates that the active user base has expanded to 1.2 million, reflecting a 30% increase year-over-year[1]. - User data showed a growth in active users, reaching 10 million, which is a 15% increase compared to the previous year[103]. - Market expansion plans include entering three new international markets by Q3 2024, aiming for a 30% increase in market share[102]. - The company is actively pursuing market expansion strategies, targeting Southeast Asia and Europe for new market entries in 2025[1]. - The company is considering strategic acquisitions to bolster its product offerings, with a target of completing at least two acquisitions by the end of 2024[104]. Research and Development - The company has allocated 15% of its revenue towards R&D, emphasizing its commitment to innovation and new technology development[1]. - The company is investing heavily in R&D, with a budget increase of 25% to enhance technology development and innovation[103]. - Research and development (R&D) expenses amounted to approximately ¥419.91 million, reflecting a decrease of 4.14% compared to the same period last year[47]. - The company has a robust R&D pipeline with 362 R&D personnel, accounting for 30.91% of the total workforce, which is an increase from 28.70% in the previous year[57]. - The company is committed to enhancing its research and development capabilities to support future growth and product launches[27]. Product Development and Pipeline - New product development includes the launch of two innovative drugs, which are expected to enter clinical trials by Q4 2024[1]. - The company is developing multiple innovative drugs and biosimilars targeting major diseases, including cancer and autoimmune diseases[27]. - The company has established partnerships for BAT1706's commercialization in China, Europe, the US, and emerging markets, enhancing market reach[30]. - The company has submitted marketing authorization applications for BAT2206 and has six products in Phase III or pivotal registration studies[27]. - The company aims to adhere to the "Innovation Only for Life" philosophy, focusing on innovative drug development[27]. Financial Stability and Cash Flow - The company has maintained a strong cash position with 200 million RMB in cash reserves, ensuring financial stability for upcoming projects[1]. - The net cash flow from operating activities improved, with a net outflow of CNY -63,260,076.28, a decrease of CNY 155,426,809.31 from the previous year[18]. - The company's cash and cash equivalents increased significantly to RMB 278,358,509.85 from RMB 163,986,759.82, marking a growth of approximately 69.5%[152]. - The company has a total of 362 R&D personnel as of June 30, 2024, accounting for 30.91% of the workforce, including 18 PhD holders and 126 master's degree holders[67]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company faces significant industry risks due to intense competition in the biopharmaceutical market, which may impact pricing and market share[74]. - The global economic slowdown poses a risk to the company's future business and financial performance, potentially affecting profitability[75]. - The company is at risk of losing key technical personnel, which could delay the development of its in-progress products[72]. Corporate Governance and Compliance - No significant changes in corporate governance or related party transactions were reported during this period[1]. - The management emphasized the importance of adhering to shareholder commitments and regulatory requirements regarding stock transfers[108]. - The company has established various governance rules to protect minority shareholders, but risks remain regarding potential undue influence from major shareholders[76]. - The company has implemented a stock lock-up period for key personnel, lasting 12 months post-IPO[108]. Environmental Responsibility - The company achieved compliance with all pollutant discharge standards, with no exceedances reported during the period[92]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[99]. - The company has established a self-monitoring plan for environmental compliance, with all monitoring results meeting regulatory requirements[98]. Legal Matters - The company reported a significant legal dispute involving a construction contract, with a total amount of 25,346,971.34 RMB frozen until January 11, 2025[133]. - The company faced a lawsuit from Wang Shengwu regarding contract disputes, which was dismissed in April 2024, indicating a favorable outcome for the company[134].

中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）首次公开发行 股票并在科创板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上 海证券交易所科创板股票上市规则》《科创板上市公司持续监管办法（试行）》和 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规 定，对百奥泰拟使用部分闲置募集资金暂时补充流动资金事项进行了核查，具体 核查情况如下： 一、募集资金基本情况 经上海证券交易所科创板上市委员会2019年11月20日审核同意，并经中国证 券监督管理委员会2020年1月14日《关于同意百奥泰生物制药股份有限公司首次 公开发行股票注册的批复》（证监许可[2020]92号）注册同意，公司公开发行人 民币普通股6,000万股，发行价格为人民币32.76元/股。募集资金总额为人民币 196,560.00万元，扣除发行费用后，募集资金净额为人民币187,619.98万元。以上 募集资金到位情况已经由安永华明会计师事务所（特殊普通合伙）审验并于 ...

百奥泰生物制药股份有限公司 关于公司 2024 年度提质增效重回报专项行动方案的 半年度评估报告 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）为践行"以 投资者为本"的发展理念，推动公司持续优化经营、规范治理和积极回报投资者， 大力提高公司质量，助力信心提振、资本市场稳定和经济高质量发展，基于对公 司未来发展前景的信心、对公司价值的认可和切实履行社会责任，公司制定并发 布了《百奥泰生物制药股份有限公司 2024 年度 "提质增效重回报"行动方案》。 2024 年上半年，公司在产品研发、市场开拓、产能提升、公司管理、投资者 沟通等多方面争取了一系列进展，进一步夯实了企业核心竞争力，提高了公司内 生价值。公司就 2024 年上半年行动方案主要举措的进展及成效情况报告如下： 一、推进研发项目，提升公司核心竞争能力的实施情况 2024 年上半年，公司合理配置资源，制订了科学合理的临床开发策略，与药 品监管机构保持积极沟通，高质量推进各项研发项目。公司围绕战略方向，持续 加强研发投入，上半年研发投入 40,252.33 万元，占营业收入的 100.06%。 公司拥有卓越的创新药研发能力，目前，公司已构建 ...

证券代码：688177 证券简称：百奥泰 公告编号：2024-043 百奥泰生物制药股份有限公司 第二届监事会第十五次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 经审议，监事会认为公司 2024 年半年度报告的编制和审议程序符合相关法 律法规及公司章程等内部规章制度的规定；公司 2024 年半年度报告的内容与格 式符合相关规定，公允地反映了公司 2024 年半年度的财务状况和经营成果等事 项；半年度报告编制过程中，未发现公司参与半年度报告编制和审议的人员有违 反保密规定的行为；监事会全体成员保证公司 2024 年半年度报告披露的信息真 实、准确、完整，不存在任何虚假记载、误导性陈述或重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 具体内容参见公司于 8 月 23 日在上海证券交易所网站（www.sse.com.cn） 和指定媒体刊登的《百奥泰生物制药股份有限公司 2024 年半年度报告》及《百 奥泰生物制药股份有限公司 2024 年半年度报告摘要》。 表决结果：3 票赞成、0 票反对 ...

证券代码：688177 证券简称：百奥泰 公告编号：2024-044 百奥泰生物制药股份有限公司 关于使用部分闲置募集资金暂时补充流动资金 的公告 重要内容提示： 百奥泰生物制药股份有限公司（以下简称"公司"或"百奥泰"）拟使用不 超过人民币 1 亿元闲置募集资金暂时补充流动资金，并仅用于公司的业务拓展、 日常经营等与主营业务相关的生产经营使用，不会通过直接或间接安排用于新股 配售、申购，或用于股票及其衍生品种、可转债等交易，不会变相改变募集资金 用途，不会影响募集资金投资计划的正常进行。 使用期限自公司董事会审议通过之日起不超过 12 个月，到期归还至募集 资金专用账户。 截至本公告披露日，公司已将前次用于暂时补充流动资金的募集资金全 部归还至募集资金专户。 公司于 2024 年 8 月 22 日召开第二届董事会第十七次会议、第二届监事会第 十五次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》。 根据募集资金投资项目的资金使用计划及项目的建设进度，公司在确保不影响募 集资金投资项目建设进度的前提下，为了提高募集资金使用效率、降低公司财务 成本，董事会同意公司使用部分闲置募集资金暂时补充流 ...

证券代码：688177 证券简称：百奥泰 公告编号：2024-042 截至本公告披露日，公司已将上述暂时补充流动资金的 1 亿元闲置募集资金 全部归还至募集资金专用账户，并将上述募集资金的归还情况通知了保荐机构和 保荐代表人。 特此公告。 百奥泰生物制药股份有限公司董事会 2024 年 8 月 22 日 百奥泰生物制药股份有限公司 关于归还暂时用于补充流动资金的闲置募集资金的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 百奥泰生物制药股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日召开 第二届董事会第十次会议和第二届监事会第九次会议，审议通过了《关于使用部 分闲置募集资金暂时补充流动资金的议案》，同意公司在确保不影响募集资金投 资项目实施及募集资金使用的情况下，使用不超过人民币 1 亿元闲置募集资金暂 时补充流动资金，使用期限自董事会审议通过之日起不超过 12 个月。具体内容 详见公司于 2023 年 8 月 25 日在上海证券交易所网站（www.sse.com.cn）和指定 媒体刊登的《百奥 ...

证券代码： 688177 证券简称： 百奥泰 公告编号：2024-041 百奥泰生物制药股份有限公司 关于 Avzivi®（贝伐珠单抗注射液）获 欧盟委员会上市批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于近日收到 欧盟委员会通知，Avzivi®（BAT1706，贝伐珠单抗注射液）获得欧盟委员会上 市批准，用于治疗转移性结直肠癌、转移性乳腺癌、非小细胞肺癌、肾细胞癌、 上皮性卵巢癌、输卵管癌或原发性腹膜癌、宫颈癌。 现将相关情况公告如下： 上市许可编号：EU/1/24/1834/001、EU/1/24/1834/002 二、 药品其他相关情况 BAT1706是百奥泰根据中国国家药品监督管理局（NMPA）、美国食品药 品监督管理局（FDA）、欧洲药品管理局（EMA）生物类似药相关指导原则开 发的贝伐珠单抗注射液。BAT1706（贝伐珠单抗注射液）是一种人源化单克隆 抗体，属于血管内皮生长因子（VEGF）抑制剂，其通过与VEGF结合，阻断 VEGF与其受 ...

Financial Performance - The net profit attributable to the parent company is expected to be between -220 million and -280 million yuan for the first half of 2024, continuing to incur losses compared to the same period last year [7]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be between -250 million and -310 million yuan [15]. - The company's operating revenue is expected to increase by 60 million to 90 million yuan compared to the same period last year, driven by market expansion and increased sales of the drug Geleli [12]. - The performance for the first half of 2024 shows no significant changes compared to the same period last year [12]. Sales and Market Expansion - The overseas sales revenue has increased year-on-year following the approval and launch of the drug Tocilizumab injection in the US in May 2024 [12]. Earnings Forecast and Risks - The company confirms that there are no significant uncertainties affecting the accuracy of this earnings forecast [4]. - The earnings forecast has not been audited by a registered accountant [10]. - The company emphasizes the importance of investors being aware of investment risks related to the preliminary earnings data [10]. - The board of directors guarantees the truthfulness, accuracy, and completeness of the announcement content [6]. - The company will provide more accurate financial data in the official 2024 semi-annual report [10].

特此公告。 根据协议约定，百奥泰于 2024 年 7 月 24 日收到由 Hikma 支付的 1,000 万 美元里程碑付款（实际到账金额须扣除银行手续费），按照当天中国人民银行公 布的美元兑人民币中间价 7.1358，共计人民币 7,135.8 万元。该里程碑付款的到 账，进一步充盈了公司的现金储备，也为公司后续管线研发和国际化战略的推 进提供助力。 截至本公告披露日，百奥泰 BAT2206（乌司奴单抗）注射液已向国家药品 监督管理局（NMPA）、美国食品药品监督管理局（FDA）、欧洲药品管理局 （EMA）提交上市申请并获得受理。 协议履行的风险详见公司于 2021 年 8 月 28 日披露的《百奥泰生物制药股 份有限公司关于与 Hikma Pharmaceuticals USA Inc.就 BAT2206（乌司奴单抗） 注射液签署授权许可与商业化协议的公告》（公告编号：2021-042）之"五、 协议履行的风险分析"。 敬请广大投资者注意投资风险，公司将严格按照有关规定及时对本协议后 续进展情况履行信息披露义务。 证券代码：688177 证券简称：百奥泰 公告编号：2024-039 百奥泰生物制药股份有限 ...

Financial Data and Key Metrics - The company has already put into production 30,500L capacity, with an additional 36,000L capacity expected to be completed by the end of July [5] - The global biopharmaceutical market is projected to reach approximately $70 billion in the next 5 years, with 60% in the US, 30% in Europe, and 10% in other regions [6] Business Line Data and Key Metrics - TOFIDENCE (tocilizumab injection) and Avzivi® (bevacizumab injection) are being commercialized in Europe and the US, with pricing strategies differing from competitors [3] - BAT8006, a FRα ADC product, has shown superior anti-tumor activity in platinum-resistant ovarian cancer patients with FRα expression levels of TPS≥1% [19] - Betanine® (bevacizumab citrate injection) has shown a 43% risk reduction in clinical studies compared to 16% for similar products [12] Market Data and Key Metrics - The US is the primary market for biologics, with recent FDA and CMS policies favoring the rapid entry of biosimilars into the market [6] - TOFIDENCE began sales in the US in May, with market expansion expected to take time [15] Company Strategy and Industry Competition - The company is preparing to compete in global markets, particularly in the face of potential centralized procurement in China [1][9] - The company is focusing on expanding its production capacity and preparing for market entry of new products [5][12] Management Commentary on Operating Environment and Future Outlook - The company believes that the biopharmaceutical sector will be less affected by US election outcomes, as the focus is more on industries like electric vehicles and electronics [13] - The company is optimistic about the supportive policies for innovative drugs and biopharmaceuticals in China, particularly in Guangzhou [14] Other Important Information - BAT8006 received FDA IND approval in March for Phase II clinical trials in platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [8] - The company is exploring the feasibility of combining BAT8006 with bevacizumab and PD1 for treatment [8] Q&A Session Summary Q1: Impact of potential US tariffs on Chinese goods and company strategy - The company is prepared to compete in centralized procurement scenarios, focusing on production cost competitiveness [1] Q2: Future centralized procurement possibilities for adalimumab and bevacizumab - The company is considering global market competition and preparing for potential centralized procurement [9] Q3: Support measures for innovative drugs in China - The company highlights supportive policies at both national and local levels, particularly in Guangzhou [14] Q4: Sales progress of tocilizumab and bevacizumab in Europe and the US - The company notes that pricing strategies differ from competitors and that market expansion will take time [3][15] Q5: Impact of US-China relations on BD transactions and agreements - The company has not observed any significant impact on BD transactions due to US-China relations [2] Q6: Current and future production capacity - The company has 30,500L capacity in production and expects to complete an additional 36,000L by the end of July [5] Q7: Sales strategy and pricing for tocilizumab and bevacizumab in Europe and the US - The company's partners determine the commercialization strategy, with pricing differing from competitors [3] Q8: Market share in regions outside the US - The company did not provide specific details on market share outside the US [17] Q9: Timeline for biosimilar entry into the US market - It may take six months or more for a biosimilar to enter the US market after approval, with additional time needed to gain market share [20] Q10: Commercialization plans for bevacizumab - The company did not provide specific details on commercialization plans for bevacizumab [4] Q11: Market sales expectations for bevacizumab - The company notes uncertainty in market expectations due to factors like医保准入 [21] Q12: Advantages of FRα ADC and future clinical development plans - BAT8006 has shown superior anti-tumor activity and safety in early data, with plans for further clinical trials [19]